Ftse Mib
34.467,67
0,02%
DAX
18.691,32
0,05%
S&P 500
5.267,84
-0,74%
NASDAQ
16.736,03
-0,39%
Bitcoin
67.547,77
-2,25%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CytomX Therapeutics Inc (CTMX) CytomX Therapeutics Inc (CTMX) Notizie

CTMX

CytomX Therapeutics (CTMX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CTMX
DataOraFonteTitoloSimboloCompagnia
22/05/202422:05GlobeNewswire Inc.CytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
17/05/202423:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CTMXCytomX Therapeutics Inc
17/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTMXCytomX Therapeutics Inc
16/05/202422:15GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
13/05/202422:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422:10GlobeNewswire Inc.CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422:10GlobeNewswire Inc.CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)NASDAQ:CTMXCytomX Therapeutics Inc
08/05/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTMXCytomX Therapeutics Inc
07/05/202422:15GlobeNewswire Inc.CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)NASDAQ:CTMXCytomX Therapeutics Inc
01/05/202414:00GlobeNewswire Inc.CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024NASDAQ:CTMXCytomX Therapeutics Inc
08/04/202414:00GlobeNewswire Inc.CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
03/04/202414:00GlobeNewswire Inc.CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
21/03/202413:00GlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Zhen Su to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
18/03/202413:00GlobeNewswire Inc.CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with AstellasNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421:10GlobeNewswire Inc.CytomX Therapeutics Reports 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
11/03/202421:00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTMXCytomX Therapeutics Inc
11/03/202411:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:CTMXCytomX Therapeutics Inc
04/03/202414:00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024NASDAQ:CTMXCytomX Therapeutics Inc
27/02/202414:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
24/01/202414:00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2bNASDAQ:CTMXCytomX Therapeutics Inc
12/01/202414:00GlobeNewswire Inc.CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
04/01/202414:00GlobeNewswire Inc.CytomX Therapeutics Outlines 2024 Company Priorities and MilestonesNASDAQ:CTMXCytomX Therapeutics Inc
21/12/202314:00GlobeNewswire Inc.CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
07/11/202322:15GlobeNewswire Inc.CytomX Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
01/11/202313:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
31/10/202313:00GlobeNewswire Inc.CytomX Therapeutics to Report Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:CTMXCytomX Therapeutics Inc
30/10/202313:00GlobeNewswire Inc.CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b at the SITC 2023 Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
18/10/202322:30GlobeNewswire Inc.CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugate CX-2051 at 2023 World ADC ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
05/09/202322:05GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CTMX

La tua Cronologia

UNSW3
UNVETH
Unvest
LQID
ADHBTC
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network